Celgene Corporation (NASDAQ: CELG) today announced the successful pricing of two series of senior unsecured notes for an aggregate principal amount of $1.5 billion. Of these notes, $500 million will mature in 2017 and will bear interest at an annual rate of 1.900%, and $1 billion will mature in 2022 and will bear interest at an annual rate of 3.250%. The 1.900% notes due 2017, and the 3.250% notes due 2022 were priced to yield 1.945% and 3.256%, respectively.
Celgene expects to use the net proceeds from the offering for general corporate purposes, which may include, without limitation, further development of Celgene’s clinical and pre-clinical programs, capital expenditures, general corporate development activities and meeting working capital needs. The offering is expected to close on August 9, 2012.
BofA Merrill Lynch, J.P. Morgan, and Morgan Stanley are acting as joint book-running managers. A copy of the prospectus supplement and the accompanying base prospectus, which is filed as part of Celgene’s effective shelf registration statement on Form S-3 (File No. 333-169731), may be obtained from any of the joint book-running managers by calling BofA Merrill Lynch toll-free at: 1-800-294-1322, J.P. Morgan collect at 1-212-834-4533 or Morgan Stanley toll-free at 1-866-718-1649.
An electronic copy of the prospectus supplement and the accompanying base prospectus may also be obtained at no charge at the Securities and Exchange Commission’s website at www.sec.gov.The notes are being offered pursuant to an effective registration statement on Form S-3 (File No. 333-169731) that Celgene previously filed with the Securities and Exchange Commission. This press release does not constitute an offer to sell or a solicitation of an offer to buy the notes described herein, nor shall there be any sale of these notes in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the laws of such jurisdiction. The offering of the notes will be made only by means of a prospectus supplement and the accompanying base prospectus.